Abstract
Clonal lymphoproliferative diseases of large granular lymphocytes (LGL) arise from both CD3-negative and CD3-positive cells, which define NK and T-LGL leukemia, respectively. Chronic neutropenia and anemia represent the most common clinical manifestation of these diseases but lymphocyte infiltration into bone marrow, spleen, and liver also occurs in some cases. The mechanism(s) responsible for expansion of the LGLs are unknown and the impact of lymphocytosis on the development of cytopenias is also incompletely defined. In this review, we discuss the incidence, clinical presentation, diagnostic criteria, and possible mechanisms of LGL leukemia pathogenesis. Despite the indolence of most cases of LGL leukemia, approximately 65% of patients will require therapy. There have been few controlled clinical trials conducted in this disease and long-term treatment is often required for sustained disease control. Novel therapies are primarily directed toward the targeted disruption of LGL leukemia survival. Conventional and novel therapeutics are discussed.
Keywords: LGL leukemia, large granular lymphocytes, NK-cell leukemia, T-cell leukemia, tipifarnib, alemtuzumab, siplizumab, immunosuppression
Current Cancer Therapy Reviews
Title: Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Volume: 3 Issue: 2
Author(s): Edna Ku, Todd Alekshun, Thomas P. Loughran, Lubomir Sokol and Pearlie K. Epling-Burnette
Affiliation:
Keywords: LGL leukemia, large granular lymphocytes, NK-cell leukemia, T-cell leukemia, tipifarnib, alemtuzumab, siplizumab, immunosuppression
Abstract: Clonal lymphoproliferative diseases of large granular lymphocytes (LGL) arise from both CD3-negative and CD3-positive cells, which define NK and T-LGL leukemia, respectively. Chronic neutropenia and anemia represent the most common clinical manifestation of these diseases but lymphocyte infiltration into bone marrow, spleen, and liver also occurs in some cases. The mechanism(s) responsible for expansion of the LGLs are unknown and the impact of lymphocytosis on the development of cytopenias is also incompletely defined. In this review, we discuss the incidence, clinical presentation, diagnostic criteria, and possible mechanisms of LGL leukemia pathogenesis. Despite the indolence of most cases of LGL leukemia, approximately 65% of patients will require therapy. There have been few controlled clinical trials conducted in this disease and long-term treatment is often required for sustained disease control. Novel therapies are primarily directed toward the targeted disruption of LGL leukemia survival. Conventional and novel therapeutics are discussed.
Export Options
About this article
Cite this article as:
Ku Edna, Alekshun Todd, Loughran P. Thomas, Sokol Lubomir and Epling-Burnette K. Pearlie, Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment, Current Cancer Therapy Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339407780618452
DOI https://dx.doi.org/10.2174/157339407780618452 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Caffeic Acid Phenethyl Ester (CAPE), Active Phenolic Compound of Propolis Attenuates Endothelin, Prostaglandin F2α and U46619 Elicited Contractions of Isolated Human Umbilical Artery
Current Traditional Medicine Mechanisms of Thrombosis, Available Treatments and Management Challenges Presented by Thromboangiitis Obliterans
Current Medicinal Chemistry microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Comparison of Clinical Features at the Onset of Takayasu’s Arteritis According to Age and Sex
Current Vascular Pharmacology Synthesis and Evaluation of Haloacetyl, α-Bromoacryloyl and Nitrooxyacetyl Benzo[b]furan and Benzo[b]thiophene Derivatives as Potent Antiproliferative Agents Against Leukemia L1210 and K562 Cells
Letters in Drug Design & Discovery ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology The Role of Selectins During Lung Inflammation and Their Potential Impact for Innovative Therapeutic Strategies
Current Respiratory Medicine Reviews Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Modulation of Angiotensin II Effects, A Potential Novel Approach to Inflammatory and Immune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Oral Contraceptives and Autoimmune Diseases
Current Women`s Health Reviews Cellulitis-Like Sweet Syndrome Preceding Multiple Myeloma. A Case Report
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Adult Stem Cells and the Clinical Arena: Are we Able to Widely Use this Therapy in Patients with Chronic Limbs Arteriopathy and Ischemic Ulcers without Possibility of Revascularization?
Cardiovascular & Hematological Agents in Medicinal Chemistry Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Neuropeptide/Receptor Expression and Plasticity in Micturition Pathways
Current Pharmaceutical Design The Promotional Effect of Mesenchymal Stem Cell Homing on Bone Tissue Regeneration
Current Stem Cell Research & Therapy